Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass

Masahiko Narita, Kentaro Shirakura, Eijiro Hikasa, Hana Fukuta, Yuya Tamaru, Tomoki Nakatsu, Takayuki Kadohama, Nobuyuki Akasaka, Hiroyuki Kamiya · 2026

Read Feasibility and safety of intravenous tolvaptan administration immediately upon ICU admission after cardiac surgery with cardiopulmonary bypass by Masahiko Narita, Kentaro Shirakura, Eijiro Hikasa, Hana Fukuta, Yuya Tamaru, Tomoki Nakatsu, Takayuki Kadohama, Nobuyuki Akasaka, Hiroyuki Kamiya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w7212146527.txt.

Description

Masahiko Narita leads a team in Japan that tests a new drip drug for heart surgery patients. The drug helps the body shed water as urine. Heart surgery with a bypass machine leaves many patients with fluid to clear. Proof for the drug in this setting is thin. The team gave it to some patients right on arrival in intensive care, and set them by matched peers who did not get it.

The drug group showed sound early urine flow. Their fluid balance also slid into the red at a calm, steady pace. Salt and mineral shifts in the blood did not rise in the group. No patient in either arm had a sharp drop in kidney work. The same calm held for those whose kidneys were weak to start. The team calls the drug safe to use in this slot.

Catalog record

CREATORMasahiko Narita, Kentaro Shirakura, Eijiro Hikasa, Hana Fukuta, Yuya Tamaru, Tomoki Nakatsu, Takayuki Kadohama, Nobuyuki Akasaka, Hiroyuki Kamiya
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEOpenAlex / Surgery Today

Source: https://doi.org/10.1007/s00595-026-03470-2

Browse the full library · About the Tower of Babel